How Mackin was paid
$6.9M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| J. Patrick MackinChairman, President and Chief Executive Officer | $835,145 | $5,006,990 | $991,368 | $49,605 | $6,883,108 |
| Lance A. BerryExecutive Vice President, Chief Operating Officer, Chief Financial Officer, and Treasurer | $526,377 | $1,959,984 | $400,194 | $90,536 | $2,977,091 |
| Jean F. HollowaySenior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer | $438,408 | $1,190,001 | $260,208 | $20,980 | $1,909,597 |
| John E. DavisSenior Vice President, Chief Commercial Officer | $441,095 | $1,234,977 | $261,803 | $20,172 | $1,958,047 |
| Marshall S. StantonSenior Vice President, Clinical Research and Chief Medical Officer | $443,929 | $934,986 | $263,485 | $17,993 | $1,660,393 |
What changed and why
- $6.9MCEO total compensation increased to $6,883,108 in fiscal 2025 compared to $5,511,940 in the prior year.
- 97%Stockholders strongly supported executive compensation with 97% of votes cast in favor for 2024 pay.
- Lance A. Berry was appointed Chief Operating Officer in August 2025 alongside his CFO and Treasurer roles.
- 118.7%Annual performance stock units paid out at 118.7% of target based on financial performance.
- 50%Short-term cash bonuses utilized revenue and adjusted EBITDA performance components weighted equally at 50%.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.